@article{ref1,
title="Tolerance and safety of enalapril",
journal="British journal of clinical pharmacology",
year="1984",
author="McFate Smith, W. and Davies, R. O. and Gabriel, M. A. and Kramsch, D. M. and Moncloa, F. and Rush, J. E. and Walker, J. F.",
volume="18",
number="Suppl 2",
pages="249S-253S, 255S",
abstract="Enalapril is the result of a targeted research programme to develop a non-mercapto converting enzyme inhibitor with a long duration of action and an improved safety profile for use in the therapy of hypertension and congestive heart failure. Over 3500 patients world-wide have received enalapril or enalaprilat. Long-term experience at present includes over 2500 patients. While enalapril and captopril produce similar efficacy, enalapril is better tolerated and appears not to be associated with occurrence of captopril-type side-effects, particularly the skin rash, taste loss, leukopenia and proteinuria. Enalapril and other converting enzyme inhibitors may be associated with renal insufficiency when given to patients with bilateral renovascular hypertension.<p /><p>Language: en</p>",
language="en",
issn="0306-5251",
doi="",
url="http://dx.doi.org/"
}